The Middle East pharmaceutical market is diverse, with a significant presence of leading global players alongside domestic pharmaceutical companies such as Ibrahim, Bilim and Deva. The market dynamics are further shaped by the presence of several leading suppliers of branded generics and APIs (active pharmaceutical ingredients) such as Teva, Hikma, Ibrahim, etc. Although, Middle East countries were a late entrant to the biotech sector, countries like Turkey, Saudi Arabia, UAE and Israel has made a dramatic progress in recent years, which was mainly due to several government initiatives. Moreover, several public-private partnerships also boosted the growth of pharmaceutical sector in the Middle East region. ‘The Middle Eastern Pharmaceutical Market Outlook To 2014’ report gives a strategic insight into the leading ATC classes, brands and key pharmaceutical players in the Middle East market. The top 10 brands and companies were selected from a pool of Middle East drug majors and were later rank-ordered and profiled based on revenues and market share presence in the Middle East market in 2008. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players in the Middle East market. Furthermore, it highlights the key market and R&D trends that may influence treatment sales; with a thorough analysis of the competitive dynamics of leading brands within each country and indication, in order to enable the reader to identify growth trends, key drug classes and leading players through 2014
(0 items)
